Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223357 | 0.88 | — | — | |
| SCHEMBL5576839 | 0.79 | TK2 (0.39) | TERTTK2 | |
| SCHEMBL2112758 | 0.73 | TYMP (0.40) | — | |
| SCHEMBL5134596 | 0.71 | TK1 (0.40) | TK2 | |
| SCHEMBL14354368 | 0.70 | TYMP (0.38) | — | |
| SCHEMBL9294173 | 0.70 | TYMP (0.37) | TK2 | |
| SCHEMBL6066038 | 0.70 | RNASE1 (0.42) | TK2 | |
| SCHEMBL439033 | 0.70 | RNASE1 (0.39) | TK2 | |
| SCHEMBL8592454 | 0.70 | RNASE1 (0.44) | TERTTK2 | |
| SCHEMBL6271568 | 0.69 | TK1 (0.33) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1743901-A2 | Oligonucleotides having A-DNA or B-DNA form | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-7119184-B2 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1222309-B1 | HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF | ISIS PHARMACEUTICALS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1100809-B1 | RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED | ISIS PHARMACEUTICALS INC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-6617442-B1 | Divided into two portions, one of which supports cleavage of target RNA; use in enhancing antisense therapies | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | TERT 3287/4885TK2 1005/4885 |
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | TERT 1557/4885TK2 272/4885 |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | TERT 3287/4885TK2 1005/4885 |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | TERT 1672/4885TK2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.